Vascular Ulcer Treatment Market - Analysis, Size, Share, Growth, Trends and Forecast 2021 – 2028 | Bristol Myers Squibb Co., Sanofi, Bayer AG, Pfizer Inc., Novo Nordisk A/S, and Cadila Pharmaceuticals Ltd.

Vascular ulcers are also known as stasis ulcer, venous insufficiency, stasis dermatitis, varicose ulcer, and ulcus cruris. A vascular ulcer is caused by poor vein function. Ulcers are more common in those over the age of 65. A visit to the primary care physician, a wound care expert, a vascular therapy specialist, or a dermatologist is typical for lower extremity ulcers. The majority of vascular ulcers in humans are chronic or recurrent. These are to responsible for a number of illnesses, particularly in those who have peripheral vascular disease, which causes work incapacity and terrible pain.


Generally, non-operative therapy approaches are used to gently treat vascular ulcers. When vascular ulcers are surgically repaired, STSG (Split-Thickness Skin Grafts) are used to cover the damaged regions using conventional methods. Because of the number of morbidities linked with obese people, the prevalence rate of vascular ulcers treatment market rises in tandem with the incidence of obesity.


The market for the vascular ulcers treatment is globally fragmented into diseases type, treatment type, and distribution channel.


On the basis of diseases type, the global market is segregated into:

• Neurotropic ulcers

• Diabetic ulcers

• Arterial ulcers

• Venous ulcers

• Others.

On the basis of treatment type, the market is categorized into:

• Compression

• Dressings

• Skin grafting

• Drugs

• Surgical therapy

• Others.

The compression segment is further sub-segmented into:

• Intermittent pneumatic compression

• Gradual compression.

The drugs segment is sub-classified into:

• Antibiotics

• Topical steroids,

• Pentoxifylline

• Aspirin.

On the basis of distribution channel, the market is divided into:

• Retail pharmacies

• Drugstores

• Hospital pharmacies

• Online pharmacies

• E-commerce

• Others.

The growth in the frequency of individuals suffering from hypertension and the increase in the instances of vascular disorders are the main factors driving the vascular ulcers treatment market. Because of the shift in lifestyle coupled with the rising prevalence of obesity, there has been a growth in the number of individuals suffering from chronic diseases such as vascular disease and diabetes in recent years; this is expected to drive the vascular ulcers treatment market.


The major players operating in the global vascular ulcers treatment market include Bristol Myers Squibb Co., Sanofi, Bayer AG, Pfizer Inc., Novo Nordisk A/S, and Cadila Pharmaceuticals Ltd.